Grand SLAM study protocol: a prospective randomised multicentre study of shortened versus standard duration adjuvant immune checkpoint inhibition for stage IIB-C, III and IV cutaneous melanoma

Abstract Background Adjuvant treatment with PD-1 inhibitors for 12 months has been the established standard of care for patients with resected stage IIB-IV cutaneous melanoma. In other solid tumours (e.g. breast and colorectal), a shorter duration of adjuvant chemotherapy has been shown to be non-in...

Descripció completa

Dades bibliogràfiques

Autors principals:	Patric Ejder, Henrik Jespersen, Micaela Hernberg, Lars Ny, Ana Carneiro, Sander Ellegård, Kalle Mattila, Roger Olofsson Bagge, Georgios Fountoukidis, Yvonne Brandberg, Mario Mandala, Brent O´Carrigan, Bastian Schilling, Ana Aranche, Omid Hamid, Anders Berglund, Hildur Helgadottir, Gustav Ullenhag
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2026-03-01
Col·lecció:	BMC Cancer
Matèries:	Cutaneous melanoma Immunotherapy Adjuvant Neoadjuvant
Accés en línia:	https://doi.org/10.1186/s12885-026-15924-4
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!